Literature DB >> 28368462

Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies.

Jérémie Rosain1,2,3, Eva Hong2, Claire Fieschi4,5, Paula Vieira Martins1, Carine El Sissy1, Ala-Eddine Deghmane2, Marie Ouachée6, Caroline Thomas7, David Launay8,9,10,11, Loïc de Pontual12, Felipe Suarez13,14, Despina Moshous14,15, Capucine Picard14,15,16, Muhamed-Kheir Taha2, Véronique Frémeaux-Bacchi1,17.   

Abstract

Background: Patients with terminal complement pathway deficiency (TPD) are susceptible to recurrent invasive meningococcal disease (IMD). Neisseria meningitidis (Nm) strains infecting these patients are poorly documented in the literature.
Methods: We identified patients with TPD and available Nm strains isolated during IMD. We investigated the genetic basis of the different TPDs and the characteristics of the Nm strains.
Results: We included 56 patients with C5 (n = 8), C6 (n = 20), C7 (n = 18), C8 (n = 9), or C9 (n = 1) deficiency. Genetic study was performed in 47 patients and 30 pathogenic variants were identified in the genes coding for C5 (n = 4), C6 (n = 5), C7 (n = 12), C8 (n = 7), and C9 (n = 2). We characterized 61 Nm strains responsible for IMD in the 56 patients with TPD. The most frequent strains belonged to groups Y (n = 27 [44%]), B (n = 18 [30%]), and W (n = 8 [13%]). Hyperinvasive clonal complexes (CC11, CC32, CC41/44, and CC269) were responsible for 21% of IMD cases. The CC23 predominates and represented 26% of all invasive isolates. Eleven of the 15 clonal complexes identified fit to 12 different clonal complexes belonging to carriage strains. Conclusions: Unusual meningococcal strains with low level of virulence similar to carriage strains are most frequently responsible for IMD in patients with TPD.
© The Author 217. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Neisseria meningitidis; complement; membrane attack complex.; primary immunodeficiency; terminal complement pathway

Mesh:

Substances:

Year:  2017        PMID: 28368462     DOI: 10.1093/infdis/jix143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years.

Authors:  Matt Shirley; Muhamed-Kheir Taha
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

2.  Terminal Complement Pathway Deficiency in an Adult Patient with Meningococcal Sepsis.

Authors:  F Staels; W Meersseman; P Stordeur; K Willekens; S Van Loo; A Corveleyn; I Meyts; G Meyfroidt; R Schrijvers
Journal:  Case Reports Immunol       Date:  2022-05-23

3.  Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017).

Authors:  Shamez N Ladhani; Helen Campbell; Jay Lucidarme; Steve Gray; Sydel Parikh; Laura Willerton; Stephen A Clark; Aiswarya Lekshmi; Andrew Walker; Sima Patel; Xilian Bai; Mary Ramsay; Ray Borrow
Journal:  BMC Infect Dis       Date:  2019-06-14       Impact factor: 3.090

4.  Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies.

Authors:  Carine El Sissy; Jérémie Rosain; Paula Vieira-Martins; Pauline Bordereau; Aurélia Gruber; Magali Devriese; Loïc de Pontual; Muhamed-Kheir Taha; Claire Fieschi; Capucine Picard; Véronique Frémeaux-Bacchi
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

5.  Defective lytic transglycosylase disrupts cell morphogenesis by hindering cell wall de-O-acetylation in Neisseria meningitidis.

Authors:  Allison Hillary Williams; Richard Wheeler; Ala-Eddine Deghmane; Ignacio Santecchia; Ryan E Schaub; Samia Hicham; Maryse Moya Nilges; Christian Malosse; Julia Chamot-Rooke; Ahmed Haouz; Joseph P Dillard; William P Robins; Muhamed-Kheir Taha; Ivo Gomperts Boneca
Journal:  Elife       Date:  2020-02-05       Impact factor: 8.140

6.  Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency.

Authors:  B van den Broek; C A C M van Els; B Kuipers; K van Aerde; S S Henriet; R de Groot; M I de Jonge; J D Langereis; M van der Flier
Journal:  Clin Exp Immunol       Date:  2019-10-01       Impact factor: 4.330

7.  Clinical Outcome and Underlying Genetic Cause of Functional Terminal Complement Pathway Deficiencies in a Multicenter UK Cohort.

Authors:  Annalie Shears; Cathal Steele; Jamie Craig; Stephen Jolles; Sinisa Savic; Rosie Hague; Tanya Coulter; Richard Herriot; Peter D Arkwright
Journal:  J Clin Immunol       Date:  2022-01-27       Impact factor: 8.542

8.  Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Authors:  Catherine Weil-Olivier; Muhamed-Kheir Taha; Stéphane Bouée; Corinne Emery; Véronique Loncle-Provot; Gaëlle Nachbaur; Ekkehard Beck; Céline Pribil
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

9.  Emergence of Neisseria meningitidis Serogroup W, Central African Republic, 2015-2016.

Authors:  Thierry Frank; Eva Hong; Jean-Robert Mbecko; Jean-Pierre Lombart; Muhamed-Kheir Taha; Pierre-Alain Rubbo
Journal:  Emerg Infect Dis       Date:  2018-11       Impact factor: 6.883

10.  Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries.

Authors:  Muhamed-Kheir Taha; Joël Gaudelus; Ala-Eddine Deghmane; François Caron
Journal:  Hum Vaccin Immunother       Date:  2020-03-25       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.